Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal down2.430 -0.030 (-1.220%)
Others

10/12/2019 17:52

Sino Biopharm (01177) gets drug registration approval

[ET Net News Agency, 10 December 2019] Sino Biopharmaceutical Limited (01177) said
"Ademetionine 1,4-Butanedisulfonate for Injection" (brand name "Baixinuo"), a cholagogue
developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the company,
has obtained the approval for drug registration granted by the National Medical Products
Administration of the People's Republic of China. This product is applicable to the
prevention of intrahepatic cholestasis before and during cirrhosis and intrahepatic
cholestasis during pregnancy.
Ademetionine is a physiologically active molecule present in human body, serving as a
methyl donor and precursor of physiological sulphur compounds in various important
biochemical reactions, which are conducive to the prevention of intrahepatic cholestasis.
(RC)

Back to Others

Remark: Real time quote last updated: 18/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.